• Parkinson’s gene therapy development to restart in summer 2019

  Development of the Parkinson’s disease gene therapy that UniQure was previously involved in will be...
  Read More...

• Minerva to explore therapy in treatment-naïve schizophrenia and more

  Minerva Neurosciences’ MIN-101 (roluperidone) is being considered for a future trial in treatment-naïve schizophrenia patients...
  Read More...

• ViiV adds another innovative treatment to its growing HIV arsenal

  The FDA has approved Dovato (dolutegravir/lamivudine) for the treatment of human immunodeficiency virus (HIV) in...
  Read More...

• NDAs submitted to the FDA for the first oral GLP-1 receptor agonist

  Novo Nordisk has submitted NDAs for what could be the first ever oral GLP-1 based...
  Read More...

• HIPAA-compliant Alexa skills: a new opportunity for pharma

  Amazon announced that the Alexa Skills Kit now enables companies that are HIPAA-compliant to build...
  Read More...

• Boehringer partners PureTech to develop immuno-oncology candidates

  Boehringer Ingelheim has formed an alliance with US-based PureTech Health to develop new drug candidates...
  Read More...

• Gilead and insitro team up to develop treatment for NASH

  Gilead Sciences has partnered with insitro, a data-driven drug discovery startup, to leverage an artificial...
  Read More...

• Action Medical Research: celebrating decades of discovery

  The UK BioIndustry Association has named Action Medical Research as its charity of the year...
  Read More...

• Catalent to buy gene therapy manufacturer Paragon for $1.2bn

  Catalent, a provider of biologic drug development and manufacturing services, has signed a definitive agreement...
  Read More...

• Enesi Pharma partners with US BARDA on new flu vaccines

  UK-based Enesi Pharma has partnered with the US Biomedical Advanced Research and Development Authority to...
  Read More...